Navigation Links
Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting

KENILWORTH, N.J., May 18, 2007 /PRNewswire-FirstCall/ -- A total of 20 oral and poster presentations on clinical studies with Schering-Plough's hepatitis products, including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for chronic hepatitis C virus (HCV) infection, as well as boceprevir (SCH 503034), the company's investigational oral HCV protease inhibitor currently in Phase II clinical development, will be presented by leading researchers at the 38th annual Digestive Disease Week (DDW) meeting to be held at the Washington Convention Center in Washington, D.C., May 20-23.

Hepatitis C is the most common blood-borne infection in America and the most common form of liver disease, affecting nearly 5 million people in the United States and 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States.

PEGINTRON

Clinical investigators will present findings at DDW from numerous PEGINTRON studies evaluating patient response to therapy at certain treatment milestones, an approach that is aimed at individualizing treatment for patients. Schering-Plough also is exploring novel therapeutic approaches with PEGINTRON in combination with investigational antiviral agents to optimize treatment for patients with more difficult-to-treat forms of the disease, such as patients who were nonresponders to previous therapy.

Boceprevir (SCH 503034)

Schering-Plough is undertaking a large, fully integrated clinical development program for its oral HCV protease inhibitor boceprevir, with the goal of developing new strategies for improving treatment outcomes for patients with hepatitis C.

At DDW, Schering-Plough will present results of in vitro studies conducted in collaboration with Wyeth/ViroPharma of boceprevir in combination with their investigational non-nucl
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
2. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/29/2014)... 29, 2014  A Boston Scientific Corporation (NYSE: ... stent removability and preliminary long term stricture resolution ... the August issue of the peer-reviewed journal, Gastroenterology. ... is being conducted in 11 countries and five ... metal stents (FCSEMS) after extended indwell (i.e., up ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "China Orthopedic Instrument Industry Report, 2014-2017" report to ... population and rising proportion of reimbursement for medical expenses, ... released, with its scale presenting a CAGR of 19.2% ... are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... CB1,antagonist rimonabant to show benefits beyond weight reduction ... | March 08, 2007 | The Business Intelligence,firm ... antagonist Acomplia (rimonabant) has at least,five competitors in ... more,in earlier phases of R&D. While Acomplia received ...
... March, 9, 2007-Active Biotech (ACTI.ST), today,announced new positive clinical ... treatment of prostate cancer. , By step-wise dose escalation, ... which corresponds to a doubling of the previously,reported maximum ... a step-wise intra-patient dose-escalation enables a dose,of 1 mg/day ...
Cached Medicine Technology:Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 2Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 3Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer 2
(Date:8/31/2014)... Sunday 31 August 2014: Mortality and morbidity ... year despite good use of oral anticoagulants, according to ... General Pilot Registry. The findings were presented for the ... chairperson Professor Gregory Lip (Birmingham, UK). , Professor Lip ... focused on management practices of European cardiologists conducted since ...
(Date:8/30/2014)... Sunday 31 August 2014: A new batteryless cardiac ... by heart motion was presented at ESC Congress ... prototype device does not require battery replacement. , ... Engineering Group at ARTORG, University of Bern, Switzerland, ... medical implants. Once they reach a critically low ...
(Date:8/30/2014)... In a world where a typical response to conflict ... launches a game app to teach another way. Launched ... app is a colorful way to encourage moral values playfully. ... pulls double-duty by teaching players new ways to find happiness ... gamers for consistently taking the high road, the Ultimate Karma ...
(Date:8/30/2014)... August 31, 2014 Atlanta based automotive ... to help raise money and awareness for ALS by ... General Managers, staff, and even Vice President Jimmy Ellis ... film and can be viewed on their Youtube page; ... the challenge, general managers and staff also took the ...
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 The ... modeling the body that will reveal to users some shocking ... lead to great results in modeling looks, as well as ... the new method says that there is one unique trick ... new method indicates that despite what many people might think, ...
Breaking Medicine News(10 mins):Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2Health News:Newly Launched Ultimate Karma App Elicits Happiness in Players and Encourages Moral Values 2Health News:Jim Ellis Automotive Group Take the ALS Ice Bucket Challenge 2Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2
... 30 Physicians Healthcare,Management Group, Inc. (Phyhealth) (Pink Sheets: ... with physicians,today announced that its board of directors has ... of the Company,s outstanding Common Stock., The shares ... market price.,The purchases will be made at the Company,s ...
... (Logo: http://www.newscom.com/cgi-bin/prnh/20050825/CLTH069LOGO ), What: HCA ... 2008 @ 9:00 am CT, Where: http://www.videonewswire.com/event.asp?id=52343 , ... log on to the web at the ... HCA Healthcare, 615-344-2688, ...
... /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ("China Sky ... ), a,leading fully integrated pharmaceutical company producing over-the-counter,drugs ... today that it,recently obtained production approval from the ... two of its newly developed drugs., Sodium ...
... ANGELES, Oct. 30 Cardo Medical, a company ... the FDA 510k,clearance of its Align 360 Total ... planned for commercial release during the second quarter ... the flagship product within,its Align 360 platform which ...
... at 1:30 p.m. (Pacific); ... http://www.adventrx.com , SAN DIEGO, Oct. 30 ADVENTRX Pharmaceuticals,Inc. ... conference call with,simultaneous webcast to discuss third quarter 2008 results on ... Mark N. K.,Bagnall, Executive Vice President and Chief Financial Officer, is ...
... and David,Simon, M.D. in Southern California helps people find relief from stress ... ... investments., SAN DIEGO, Oct. 30 As ... life savings,The Chopra Center for Wellbeing is teaching those impacted how to ...
Cached Medicine News:Health News:Phyhealth Announces Stock Buyback Program 2Health News:Phyhealth Announces Stock Buyback Program 3Health News:China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs 2Health News:Cardo Medical Announces FDA Clearance of the Align 360 Total Knee System 2Health News:Cardo Medical Announces FDA Clearance of the Align 360 Total Knee System 3Health News:Turbulent Times Turn The Chopra Center Into Mecca for Calm 2
... The Leica M520 OH3 ... the best optical performance available ... innovative and unique stand. The ... lightest, has the greatest range ...
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
PS Medical lumboperitoneal catheter systems are designed to divert CSF from the lumbar subarachnoid space to the peritoneal cavity, using simplified surgical techniques....
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Medicine Products: